<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336618</url>
  </required_header>
  <id_info>
    <org_study_id>EC-236</org_study_id>
    <nct_id>NCT04336618</nct_id>
  </id_info>
  <brief_title>Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population</brief_title>
  <acronym>DFWRegistry</acronym>
  <official_title>Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perspectum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perspectum</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To build a Registry of volunteers by inviting them to get a LiverMultiScan(LMS)and collecting&#xD;
      their contact information to seek interest in participating in future studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Registry where there will be no intervention to the standard of care.Participants&#xD;
      will be required to attend a single visit that will involve having a multi-parametric MRI at&#xD;
      no cost to them. In addition, the invesigators will collect contact information of&#xD;
      participants including their email address, phone number and house address so that they can&#xD;
      be contacted to discuss possible participation in future studies which may be sponsored by&#xD;
      Perspectum or third parties, such as pharmaceutical companies, the participants personal&#xD;
      information shall never be shared with these third-parties. Additionally, the contact&#xD;
      information of the participants medical providers shall be collected so that, if requested,&#xD;
      their LMS reports can be used in their diagnostic pathway.&#xD;
&#xD;
      Imaging will be performed at two Touchstone Imaging locations, one in downtown Dallas and the&#xD;
      other in Southlake.&#xD;
&#xD;
      A total of 100 participants will be enrolled over a period of 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To build a Registry of volunteers by inviting them to get a LiverMultiScan(LMS)and collecting their contact information to seek their interest in participating in future studies</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To use multi-parametric MRI (LMS) of the liver to assess the volunteer's liver health</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liver MultiScan</intervention_name>
    <description>The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult volunteers willing to get an MRI scan for the assessment of their liver&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female volunteers aged 18 years and overâ€¢&#xD;
&#xD;
          -  Participant willing and able to give informed consent for participation in the&#xD;
             registry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant may not enter the Registry if they have any contraindication to&#xD;
             magnetic resonance imaging (standard MR exclusion criteria at the imaging center&#xD;
             including pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe&#xD;
             claustrophobia).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Duncker, MD, PhD</last_name>
    <phone>210-251-0040</phone>
    <email>carlos.duncker@perspectum.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos Pantoja, Md, PhD</last_name>
    <phone>415-812-2560</phone>
    <email>carlos.pantoja@perspectum.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Perspectum Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Duncker, MD, PhD</last_name>
      <email>carlos.duncker@perspectum.com</email>
    </contact>
    <contact_backup>
      <last_name>Carlos Pantoja, MD, PhD</last_name>
      <email>carlos.pantoja@perspectum.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

